The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

2.

Common intracellular toxin could help fight leukemia

3.

Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer

4.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

5.

Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot